{"entity":{"id":"lapis-trial","kind":"trial","name":"LAPIS","aka":[],"tldr":"The anti-stroma antibody pamrevlumab did not help people with locally advanced pancreatic cancer live longer.","summary":"LAPIS randomised patients with locally advanced, unresectable pancreatic ductal adenocarcinoma to pamrevlumab or placebo with either gemcitabine plus nab-paclitaxel or FOLFIRINOX, with the aim of increasing resection and survival. FibroGen reported in 2024 that the trial did not meet its primary overall survival endpoint.","status":"negative","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT03941093","url":"https://clinicaltrials.gov/study/NCT03941093"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["pamrevlumab","gemcitabine-nab-paclitaxel","folfirinox"],"companies":["fibrogen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03941093","phase":"3","setting":"Locally advanced unresectable pancreatic cancer: pamrevlumab with gemcitabine and nab-paclitaxel or FOLFIRINOX versus chemotherapy alone","sponsor":"FibroGen","result":"Primary overall survival endpoint not met.","started":"2019-05-10","startedType":"actual","yearReported":2024,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Pamrevlumab + chemotherapy (gemcitabine-nab-paclitaxel or FOLFIRINOX)","n":143,"value":17.25},{"name":"Placebo + chemotherapy","n":141,"value":17.94}],"hr":1.08,"ci":[0.83,1.41],"p":"0.5487","source":"https://clinicaltrials.gov/study/NCT03941093"},{"endpoint":"Progression-free survival (RECIST 1.1)","unit":"months","arms":[{"name":"Pamrevlumab + chemotherapy","n":143,"value":9.36},{"name":"Placebo + chemotherapy","n":141,"value":9.4}],"source":"https://clinicaltrials.gov/study/NCT03941093"}]},"route":"/trials/lapis-trial/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"},{"id":"pamrevlumab","kind":"drug","name":"Pamrevlumab","route":"/drugs/pamrevlumab/"}],"company":[{"id":"fibrogen","kind":"company","name":"FibroGen","route":"/companies/fibrogen/"}],"term":[{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/"}]}}